[go: up one dir, main page]

AR079700A1 - Metodo para disminuir la inmunogenicidad - Google Patents

Metodo para disminuir la inmunogenicidad

Info

Publication number
AR079700A1
AR079700A1 ARP100104885A ARP100104885A AR079700A1 AR 079700 A1 AR079700 A1 AR 079700A1 AR P100104885 A ARP100104885 A AR P100104885A AR P100104885 A ARP100104885 A AR P100104885A AR 079700 A1 AR079700 A1 AR 079700A1
Authority
AR
Argentina
Prior art keywords
variable
chain
decrease immunogenicity
immunogenicity
heavy chain
Prior art date
Application number
ARP100104885A
Other languages
English (en)
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of AR079700A1 publication Critical patent/AR079700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicacion 1: Un método para disminuir la inmunogenicidad de dominios de anticuerpo variables que comprenden una cadena liviana variable y/o una cadena pesada variable que comprende el paso de sustituir uno o más residuos de aminoácidos de la cadena liviana variable y/o la cadena pesada variable, dicho residuo se encuentra presente en la interfaz entre la cadena variable y la cadena constante de un anticuerpo de longitud total correspondiente.
ARP100104885A 2009-12-23 2010-12-22 Metodo para disminuir la inmunogenicidad AR079700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28944609P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
AR079700A1 true AR079700A1 (es) 2012-02-15

Family

ID=43733894

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104885A AR079700A1 (es) 2009-12-23 2010-12-22 Metodo para disminuir la inmunogenicidad

Country Status (17)

Country Link
US (4) US8796425B2 (es)
EP (3) EP3498731A1 (es)
JP (6) JP5914353B2 (es)
KR (3) KR101721187B1 (es)
CN (2) CN109293768A (es)
AR (1) AR079700A1 (es)
AU (1) AU2010335950B2 (es)
BR (1) BR112012017051A2 (es)
CA (1) CA2777527C (es)
CL (1) CL2012001696A1 (es)
MX (2) MX352871B (es)
PH (1) PH12012500794A1 (es)
RU (1) RU2585534C2 (es)
TW (3) TWI662128B (es)
UY (2) UY39290A (es)
WO (1) WO2011075861A1 (es)
ZA (4) ZA201202299B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
DK2307458T3 (en) * 2008-06-25 2018-07-16 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
HRP20170615T1 (hr) * 2008-06-25 2017-07-28 Esbatech, An Alcon Biomedical Research Unit Llc Stabilna i topiva protutijela koja inhibiraju vegf
KR101721187B1 (ko) * 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
PH12022550311A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
RU2018119732A (ru) * 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
US10597449B2 (en) 2015-12-04 2020-03-24 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
TW201811824A (zh) 2016-07-06 2018-04-01 美商西建公司 具有低免疫原性之抗體及其用途
CN110637030B (zh) 2017-05-31 2024-06-11 勃林格殷格翰国际有限公司 拮抗肿瘤细胞中Wnt信号传导的多肽
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
KR102567962B1 (ko) * 2018-07-18 2023-08-16 주식회사 엘지에너지솔루션 리튬 이차전지용 바나듐 양극의 전기화학적 전처리 방법 및 이에 의해 전처리된 리튬 이차전지용 바나듐 양극
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201918279D0 (en) * 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4267622A1 (en) * 2020-12-23 2023-11-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
EP4448783A1 (en) 2021-12-13 2024-10-23 Heraeus Medical GmbH Tests and methods for detecting bacterial infection
KR20250008754A (ko) * 2022-05-06 2025-01-15 누맙 세러퓨틱스 아게 면역원성이 감소된 항체 가변 도메인 및 항체
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131621A1 (en) 1992-03-18 1993-09-30 Thomas R. Sykes Selective alteration of antibody immunogenicity
ATE253593T1 (de) * 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
KR20030074839A (ko) * 2001-02-19 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
EP1656391B1 (en) * 2003-08-13 2010-10-13 Pfizer Products Inc. Modified human igf-1r antibodies
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
US8243678B2 (en) * 2008-03-10 2012-08-14 Motorola Mobility, Inc. Hierarchical pilot structure in wireless communication systems
DK2307458T3 (en) * 2008-06-25 2018-07-16 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
SI2307455T1 (sl) * 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Optimizacija topnosti imunoveziv
KR101721187B1 (ko) * 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법

Also Published As

Publication number Publication date
ZA201202299B (en) 2014-06-25
KR20170084357A (ko) 2017-07-19
CA2777527C (en) 2020-06-23
ZA201706443B (en) 2020-12-23
AU2010335950A1 (en) 2012-07-19
TWI662128B (zh) 2019-06-11
CL2012001696A1 (es) 2013-03-08
CN102686608A (zh) 2012-09-19
JP2021153603A (ja) 2021-10-07
TW201619383A (zh) 2016-06-01
EP2516461A1 (en) 2012-10-31
US20180016350A1 (en) 2018-01-18
EP3498731A1 (en) 2019-06-19
JP2013515460A (ja) 2013-05-09
KR101758703B1 (ko) 2017-07-18
US20150080555A1 (en) 2015-03-19
US8796425B2 (en) 2014-08-05
UY33154A (es) 2011-06-30
UY39290A (es) 2021-07-30
RU2585534C2 (ru) 2016-05-27
BR112012017051A2 (pt) 2017-12-05
US20210214461A1 (en) 2021-07-15
JP2016094487A (ja) 2016-05-26
CN109293768A (zh) 2019-02-01
KR20170036137A (ko) 2017-03-31
ZA201402145B (en) 2018-05-30
WO2011075861A1 (en) 2011-06-30
KR20120102061A (ko) 2012-09-17
EP4219545A1 (en) 2023-08-02
MX2012005345A (es) 2012-06-08
US20110152505A1 (en) 2011-06-23
KR101721187B1 (ko) 2017-03-29
TW201925228A (zh) 2019-07-01
JP2017121254A (ja) 2017-07-13
JP2015131855A (ja) 2015-07-23
TW201125975A (en) 2011-08-01
US9803027B2 (en) 2017-10-31
AU2010335950B2 (en) 2014-08-21
PH12012500794A1 (en) 2012-11-26
US10781268B2 (en) 2020-09-22
JP5914353B2 (ja) 2016-05-11
JP6815083B2 (ja) 2021-01-20
RU2012130945A (ru) 2014-01-27
TWI633184B (zh) 2018-08-21
JP2019141071A (ja) 2019-08-29
CA2777527A1 (en) 2011-06-30
ZA202006532B (en) 2022-04-28
MX352871B (es) 2017-12-13

Similar Documents

Publication Publication Date Title
AR079700A1 (es) Metodo para disminuir la inmunogenicidad
CL2012002125A1 (es) Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.
MX2011012415A (es) Accesorio germicida y metodos.
MX356288B (es) Anticuerpos biespecificos igg4 modificados de secuencia simetrica.
EA200970304A1 (ru) Жирные кислоты и углеводороды водорослей со средней длиной цепи
ATE500327T1 (de) Verfahren und zusammensetzungen für ethanolproduzierende cyanobakterien
CL2012002296A1 (es) Polipeptido porque comprende un dominio decimo de fibronectina de tipo iii y que se une a interleucina 23 (il-23); composicion farmacéutica que comprende dicho polipeptido; procedimiento para regular la patogenicidad de los linfocitos th17 que comprende poner en contacto el polipeptido antes mencionado con il-23.
EP2554669A4 (en) NEW ANTIBODY WITH ITS INTRODUCED MODIFICATION CENTER AND ANTIBODY FRAGMENT
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
SV2008002980A (es) Composiciones y metodos de uso para anticuerpos de dickkopf-1 y/0 -4
AR079821A1 (es) Cepas y metodo para la produccion de metionina
UY31222A1 (es) Modificación enzimática del aceite
AR067500A1 (es) Prevencion de la reduccion de enlaces de disulfuro durante la produccion recombinante de polipeptidos
BR112014001834A2 (pt) biocontrole de nematoides
UA95624C2 (ru) Способ сушки свекольного жома при незначительном содержании вредных веществ
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
PH12014502762A1 (en) Method for the degradation of keratin and use of the keratin hydrolysate produced
EA200802319A1 (ru) Способ и устройство для ремонта элементов конструкции
CO7101227A2 (es) Procedimiento de remojo previo mejorado para la conversión de biomasa
WO2009098625A3 (en) Light color tunability
ECSP11011376A (es) Dispositivo y procedimiento para la verificación y para el análisis cuantitativo de analitos, particularmente de micotoxinas
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
BR112014014977A8 (pt) concentrador solar luminescente, e gerador fotovoltaico
EA201000659A1 (ru) Ограничение нагрузки на источник питания
WO2013136242A3 (en) Methods and apparatus for emergency powering of a light source

Legal Events

Date Code Title Description
FC Refusal